Suman Dash

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Cell Cycle Arrest

Reactive Oxygen Species

Radiation Therapy

Top Venues

Cell death & disease

Molecular cancer research : MCR

This page only lists publications with an associated author ORCID identifier.

Publications

Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (5) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (5) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Masahiko Honda, Ryoichi Sugisawa, Hitoshi Okada
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer. Cell death & disease 15 (2) (2024)
Suman Dash, Takeshi Ueda, Akiyoshi Komuro, Hisayuki Amano, Masahiko Honda, Masahito Kawazu, Hitoshi Okada
MYC/glutamine dependency is a therapeutic vulnerability in pancreatic cancer with deoxycytidine kinase inactivation-induced gemcitabine resistance. Molecular cancer research : MCR (2023)